CRISPR Therapeutics
CRSP
435 hedge funds and large institutions have $3.7B invested in CRISPR Therapeutics in 2022 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 128 increasing their positions, 116 reducing their positions, and 50 closing their positions.
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
14% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 50
11% more capital invested
Capital invested by funds: $3.35B → $3.7B (+$355M)
10% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 116
1.06% more ownership
Funds ownership: 71.63% → 72.68% (+1.1%)
5% more call options, than puts
Call options by funds: $223M | Put options by funds: $213M
0% more funds holding
Funds holding: 435 → 435 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$54.2M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$49.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.2M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$20.9M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$19.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$132M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$108M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$28M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$23.3M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$23.3M |
CRSP Hedge Fund Activity: Q3 2022 in Review
435 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2022, worth a combined $3.7B — up 11% from $3.35B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new CRSP positions and 50 closed out — a net gain of 7 holders — while 128 added to existing stakes and 116 trimmed.
The largest buyer was Macquarie Group, adding an estimated $54.2M. The largest seller was T. Rowe Price Associates, cutting an estimated $132M.
- 435 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $3.7B of CRISPR Therapeutics stock for Q3 2022, up 11% quarter-over-quarter.
- 57 funds opened new CRISPR Therapeutics positions in Q3 2022 and 50 closed out, a net change of +7 holders.
- The largest CRISPR Therapeutics buyer in Q3 2022 was Macquarie Group, an estimated $54.2M added.
- The largest CRISPR Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $132M sold.
Based on aggregated 13F filings for Q3 2022.